Re: Echelon on Sernova, 4 August 2020 - Comment :)
SVA and three thin dimes... easy come, easy go... SVA closed at $0.29 on 216k (52k Germany; 1,500 shares in one trade US ) , BUT 001 and 002 were messing around on the alternate exchanges at the end of the day.
Bullish one day, bearish the next... what to say while we wait for news? Only The Computers and The Goon Squad know for sure... maybe...
The following excerpt at the very end from Doug Loe's (Echelon's) latest and scientifically oriented epistle on Sernova has finally been picked up by social media. (I use Stockhouse as the example.) I have been quiet on this, but effectively it says that some (or all) of the FDA trial cohorts no longer need insulin. Sernova has not released this publicly, but this is HUGE.
"... Though our Cell Pouch valuation is based on three distinct regenerative medicine markets (insulin-dependent type I/II diabetes, Factor VII supplementation in hemophilia A, thyroxine supplementation in post-thyroidectomy patients), we are primarily focused in the near-term on patient outcomes in the University of Chicago-based clinical trial for which early patient outcomes (sustainability of blood glucose homeostasis post-Cell Pouch implantation without exogenous insulin supplementation has been observe in early cases) have been highly encouraging."